



ASX ANNOUNCEMENT

20 October 2006

Poultry Productivity Enhancer Passes Further Safety Trials

The latest Poultry Productivity Enhancer safety trial has been successfully completed. Interim results confirm the vaccine cannot infect species other than chickens (pigeons) even if administered directly to the pigeons at the same dose given to chickens.

The trial was approved by the Office of Gene Technology Regulator in Australia (OGTR) and was undertaken to further document certain product safety parameters. The results will be submitted to enable additional regulatory approvals from the OGTR. Previous successful safety trials conducted by Imugene confirmed the vaccine cannot infect or spread to birds such as sparrows and starlings. In particular, this current trial was designed to confirm the vaccine does not infect other bird species that may be found in close proximity to commercial chickens such as pigeons. The results concur with those of previous trials, indicating the vaccine does not successfully infect birds other than the target species (chickens). This specificity is an extremely advantageous safety characteristic for future global product registration.

When received the final results will be collated and submitted to the OGTR as part of the intentional release dossier.

- ENDS -

About Imugene (ASX: IMU)

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the *Fowl Adenoviral Vector Delivery System* for poultry and the *Porcine Adenoviral Vector Delivery System* for pigs. Imugene has successfully licensed the first product based on the *Fowl Adenoviral Vector Delivery System* – the *Poultry Productivity Enhancer*.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market with four lead vaccine products under development and a strong product pipeline.

Perth Office

Level 20, Allendale Square
77 St Georges Terrace
Perth WA 6000
Tel: +61 8 9440 2660
Fax: +61 8 9440 2699

ABN: 99 009 179 551

Sydney Office

Registered Office
Level 1, 14 – 20 Delhi Road
North Ryde NSW 2113
Tel: +61 2 9870 7330
Fax: +61 2 9888 9338

www.imugene.com

Consumer demands for disease free and residue free food will bolster Imugene's prospects.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

For more information please visit the Imugene Website www.imugene.com

For more information:

Dr Warwick Lamb
Managing Director
+61 2 9870 7330

Mr Graham Dowland
Executive Chairman
+61 8 9440 2660

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333